Portfolio

Pioneering data-driven medicine company SOPHiA GENETICS raises $30m

SEP 12, 2017

We are delighted to announce today that we are leading an investment of $30m in SOPHiA GENETICS, the pioneering data-driven medicine company. Swiss-based SOPHiA has developed a platform that applies artificial intelligence to huge volumes of genomic data, to help diagnose patients’ illnesses.

Dr. Jurgi Camblong, CEO, SOPHiA GENETICS

We believe that there is an opportunity to build the defining software layer on top of technologies in genomics, just as Windows did for PCs and Android has for smartphones, and SOPHiA GENETICS is already leading in this field.

James Wise, partner, Balderton Capital

The platform is used today by over 300 hospitals and 1000s of clinicians globally, and to date has analysed genomic profiles of over 125,000 patients. The funding will accelerate SOPHiA’s vision is to build the world’s largest clinical genomics community.

You can read Balderton Partner James Wise's thoughts on the SOPHiA investment here.

Stay in touch with Balderton

Sign up for our newsletter to stay up to date on news from Balderton, and our portfolio.